Uraria picta

Uraria picta (Prishniparni): A Comprehensive Reference

1. Identity and Botanical Description

Nomenclature and Taxonomy

Uraria picta (Jacq.) DC. — known in Ayurveda as Prishniparni — is one of the most important medicinal plants used in different traditional systems of medicine, including Ayurveda and Traditional Chinese Medicine. Its accepted botanical synonyms include Doodia picta Roxb., Hedysarum pictum Jacq., Uraria aphrodisiaca Welw., U. leucantha Span., and U. linearis Hassk. (WFO, 2023). The species belongs to the family Fabaceae (Leguminosae).

The plant is known by numerous vernacular names across its range. In Ayurvedic literature the primary Sanskrit name is Prishniparni (also spelled Prishnaparni), and secondary names include Pitvan. It is commonly known as Prishniparni and has been used therapeutically as one of the key ingredients of Dashmula for decades to treat a variety of health conditions.

Morphology and Geography

Uraria picta is an erect subshrub or shrub, about 90–180 cm high. Its stem is cylindrical with short hairs. The lower leaves (1–3-foliolate) are ovate and the upper leaves (5–9-foliolate) are ovate-lanceolate; mucronulate at the apex, often variegated, glabrescent and shiny above, scabrid and strongly reticulate beneath, with mucronate apices. The plant bears purplish flowers each measuring around 6–10 mm, appearing on dense cylindrical racemes that can reach up to 20 cm in length, adorned with caducous bracts about 1.5 cm long. Flowering and fruiting occur from August to October.

The species is a woody herb found throughout Asia, Africa, and Australia. It typically grows in dry grasslands, open forests, and wastelands, and is commonly found throughout the plains of India and along the sub-Himalayan region, from Kashmir to West Bengal and Assam, up to an altitude of 1800 meters. More specifically, it is found in areas of dry grasslands, grassland with scattered trees including Acacia, waste places, rocky ground, deep sandy soils, riverbanks, floodplains, and gallery forest.

Common Forms and Preparations

For medicinal purposes, the roots, leaves, and whole plant are used. U. picta is a key ingredient of more than a hundred Ayurvedic formulations and an important component of many patents in countries like India, China, Japan, and the USA. The plant is an important ingredient of the well-established Ayurvedic formulation Dashmula, which contains roots of ten herbs. Apart from Dashmula, U. picta is also a key ingredient of more than 100 Ayurvedic formulations including Amritarishta, Dashmulachurna, Abhrak Bhasma, Brahma Rasayan, Dashmula Taila, Rajanyadi Churna, and Anu Taila.

2. Traditional and Historical Use

Ayurvedic Tradition (India)

Prishniparni (Uraria picta Desv. ex DC.) is a respected herb in Ayurveda and is described in ancient texts including the Charaka Samhita, Sushruta Samhita, Ashtanga Hridaya, and various Nighantus. It is considered an Agrayadravya (a superior medicinal substance, with Sangrahika, Vatahara, Deepniya, and Vrishya karma) in the Charaka Samhita. Its multiple therapeutic indications include Shwasa (breathing troubles), Kasa (cough), Jwara (fever), Atisara (diarrhoea), Raktavikara (bleeding disorders), Grahani (IBS), Vataroga, and Asthibhagna (bone fractures). Various medicinal preparations (Yogas) are mentioned in classical texts.

U. picta is a key component of Dashamoola, a classical group of ten roots widely used for treating various Vata-related disorders. Dashamoola is divided into two subgroups: the Brihat Panchamoola (five large tree species: Bilva, Agnimantha, Kashmari, Shyonaka, and Patala) and the Laghu Panchamoola (five smaller shrubs: Brihati, Kantakari, Shalaparni, Prishniparni, and Gokhru).

In traditional Indian medicine, the roots and leaves of Uraria picta are employed in various preparations to address fever, cough, diarrhoea, rheumatism, and as an aphrodisiac. Decoctions made from the roots are commonly administered for fever and cough, while leaf pastes serve as poultices for rheumatism and inflammatory conditions. The description of the plant can also be found in the classical ancient books of Ayurveda, such as Charak Samhita, Sushrut Samhita, and Vaghabhatta.

African and Other Traditional Systems

U. picta is traditionally used in treating gonorrhoea, malaria, hypertension, sore throat, spermatorrhoea, bleeding piles, bone fractures, cough, cold, fever, wounds, and to expel tapeworms. Ethnomedicinal applications extend beyond India to Africa and other parts of Asia, where in certain African communities crushed leaves are applied topically to treat wounds and sores, leveraging the herb's purported antimicrobial properties.

Leaves have been traditionally attributed with antiseptic properties and are used in the treatment of wounds, genitourinary infections, and urinary disorders. The powdered leaves have been used for gonorrhoea. The plant has also been used in heart troubles and as an antidote against the bites of certain vipers and scorpions.

Traditional Chinese Medicine

Prishnaparni (U. picta) is recognized as one of the most important medicinal plants used in Traditional Chinese Medicine as well as Ayurveda. Chinese traditionalists called U. picta Mei Hua Li Wei Dou. Uraria picta is traditionally used to treat several diseases in Asia, Africa, and China.

Dosage in Traditional Practice

Classical Ayurvedic texts like the Charaka Samhita provide dosage guidelines for Prishniparni, recommending 3–6 grams of root powder daily in decoction form for internal use, often combined with other herbs in Dashamoola preparations.

3. Key Phytochemical Constituents

Major Chemical Classes

Phytochemical analysis of U. picta shows various components such as alkaloids, flavonoids, steroids, terpenoids, phenols, and saponins. The phytochemical analysis of this plant has afforded an important category of natural products such as coumestans, terpenoids, alkaloids, volatile oils, flavonoids, and thiopenes. Results of systematic screening have shown the presence of alkaloids, flavonoids, steroids, terpenoids, phenols, and saponins in all plant parts. Tannins are absent in stem and roots, whereas cardiac glycosides are absent in roots.

Rhoifolin — The Principal Marker Compound

Biochemical analysis of different plant parts of U. picta and its tissue culture has shown that it is a valuable source of several bioactive phytochemicals, among which Rhoifolin is the most recognized. The major bioactive flavonoid rhoifolin (Apigenin-7-O-neohesperidoside) is considered a marker compound for qualitative and quantitative standardization of the herb. Yadav and his team reported the isolation, quantitation, and validation of the flavone glycoside Rhoifolin from aerial parts of U. picta.

Isoflavanones (Roots)

Two isoflavanones — 5,7-dihydroxy-2′-methoxy-3′,4′-methylenedioxyisoflavanone and 4′,5-dihydroxy-2′,3′-dimethoxy-7-(5-hydroxyoxychromen-7yl)-isoflavanone — along with six known compounds including isoflavanones, triterpenes, and steroids were isolated from the roots of Uraria picta. Subsequent researchers also identified stigmasta-4,22-diene-3-one, β-sitosterol, and lupeol by direct comparison of spectral data.

Full Spectrum of Identified Compounds

U. picta contains a diverse range of pharmacologically important phytochemicals, including phenolics (such as caffeic acid, gingerol, and tremetone), flavonoids (like rhoifolin and isochamaejasmin), fatty acids (stearic acid and 13-OxoODE), steroids (beta-sitostenone, limonene, and flossonol), triterpenoids, and alkaloids (such as istamycin C1, 5-methyltetrahydrofolate, and acronycine), along with amino acid-related compounds like miraxanthin-II and DL-Dopa.

Flavonoids, alkaloids, and pterocarpans are the key constituents of Uraria picta and are mainly credited for its broad beneficial actions. Macro elements including Na (0.04%), K (0.67%), Ca (1.81%), Mg (0.21%), and P (0.04%) have been quantitatively determined in the leaves; corresponding values differ in stem and roots.

The bulk of published studies focus on the plant extract rather than individual metabolites, and there is a notable dearth of reports on the mechanism of action of these phytochemicals at the molecular level.

The seeds have a good balance of essential amino acids, and the proportion of these amino acids is almost on par with that of nutritionally important common legumes and cereals.

4. Mechanisms of Action

In carrageenan-induced inflammatory models, histamine, 5-hydroxytryptamine, and bradykinin are initially detected in the first phase, followed by prostaglandins and nitric oxide because of the induction of cyclooxygenase and inducible nitric oxide synthase (iNOS). Anti-inflammatory activity of U. picta extracts is understood to operate at multiple points within this cascade, though molecular-level mechanistic studies remain limited.

Aqueous extracts of the plant have been shown to inhibit acetylcholinesterase and butyrylcholinesterase in a dose-dependent manner. Phenols and flavonoids are present in the extracts, and the extract also scavenges ABTS radical and hydroxyl radical in a dose-dependent manner. Inhibition of acetylcholinesterase and butyrylcholinesterase, together with exhibited antioxidant properties, suggests that U. picta extract may be of relevance in managing Alzheimer's disease.

Phenolic compounds in the plant show antimicrobial, antioxidant, anticarcinogenic, and anti-inflammatory effects, and contribute to inducing apoptosis by arresting the cell cycle, regulating carcinogen metabolism and oncogene expression, inhibiting DNA binding, and blocking signaling pathways. Saponins are used commercially in traditional medicine preparations and show hypocholesterolemic and antidiabetic properties. As all these phytochemical constituents are present in U. picta, all the pharmacological properties associated with these compounds are found in the plant as well.

The anticancer effects of methanolic extract of aerial parts (MEUP) are largely attributable to antioxidant, anti-inflammatory, and anticancer principles present in it.

5. Scientific Evidence by Area of Use

5.1 Anti-inflammatory Activity

Methanolic root extract of U. picta showed significant activity against both models of inflammation tested. UPME at 400, 200, and 100 mg/kg (oral) reduced inflammation in egg albumin- and formalin-treated animals in a dose-dependent manner. Extraction of methanol from U. picta roots reduced inflammation of egg albumin and formalin in a dose-dependent manner. A subsequent study performed anti-inflammatory testing against leg edema caused by carrageenan using U. picta methanol extract in albino rats.

Anti-inflammatory activity of a water decoction of roots against carrageenan-induced paw edema has also been reported. U. picta was observed to have better activity compared to other test plants (Tribulus terrestris, Stereospermum colais, Solanum virginianum, Solanum anguivi, and Gmelina arborea) both in the initial and later phases.

A study evaluated anti-inflammatory activities of whole-plant methanolic extract of P. viscida and U. picta on carrageenan-induced paw edema in albino rats. The methanolic extracts were administered orally at dose levels of 200 and 400 mg/kg body weight and compared with indomethacin as the standard reference drug. However, P. viscida had higher inhibitory activity compared to U. picta.

Evidence strength: All anti-inflammatory data are from in vitro and in vivo animal studies (rodent models). No published controlled human clinical trials on the anti-inflammatory effects of U. picta as a standalone preparation have been identified in the peer-reviewed literature.

5.2 Hepatoprotective Activity

Singh (2017) tested liver damage caused by paracetamol (2000 mg/kg) in mice, which increased blood levels of ALT, ALP, and AST. Administration of methanol extract from U. picta roots reduced ALT, ALP, and AST enzyme levels, with activity comparable to the standard drug silymarin.

Evidence strength: Preclinical animal data only. No human hepatoprotection trials have been published for U. picta as an isolated intervention.

5.3 Antioxidant Activity

The ethanolic extract of the whole plant of U. picta showed potential antioxidant activity. Preliminary phytochemical screening of the methanolic extract of aerial parts (MEUP) confirmed the presence of flavonoids, phenolics, glycosides, and tannins. Total phenolic and flavonoid contents in MEUP were found to be 14.6 gram equivalent of gallic acid and 0.735 gram equivalent of catechin, respectively.

Evidence strength: These assessments are in vitro assays. Clinical evidence in humans is absent.

5.4 Antimicrobial Activity

Two isoflavanones isolated from the roots of Uraria picta by Rahman, Gibbons, and Gray (University of Strathclyde, published in Phytochemistry, 2007), had their structures established by UV, IR, MS, and NMR analyses. The minimum inhibitory concentrations (MIC) for these compounds were found to be in the range of 12.5–200 µg/ml against bacteria (both Gram-positive and Gram-negative) and fungi.

Phytochemical screening has established the presence of flavonoids in all extracts, with alkaloids, amino acids, and anthraquinones prevalent only in Soxhlet-derived extracts.

Evidence strength: Antimicrobial data are from in vitro MIC studies. No clinical trials on infectious disease outcomes in humans are available.

5.5 Anticancer Activity

An investigation was conducted to evaluate the anticancer activity of the methanolic extract of aerial parts of Uraria picta. Preliminary phytochemical screening confirmed the presence of flavonoids, phenolics, glycosides, and tannins. IC50 values of cisplatin and MEUP were found to be 8.75 µg/ml and 436.92 µg/ml, respectively. Although an IC50 value of 436.92 µg/ml is too high to establish the crude methanolic extract of Uraria picta as a potential anticancer agent, the results from other in vitro and in vivo experiments in that study clearly indicate that the plant has promising anticancer properties. Further fractionation of the extract, or identification and isolation of active anticancer molecules, would be needed to find novel anticancer leads.

At a higher dose (400 mg/kg), MEUP was found more effective in reducing cancer growth. Moreover, MEUP was found to be safe, as no signs of toxicity were observed in animals receiving it, and no significant fluctuations in body weights were observed in MEUP-treated groups.

Evidence strength: Strictly in vitro and in vivo animal data (cell line and rodent models). Human oncology trials do not exist for this plant. The crude extract's IC50 is far outside the range typically considered pharmaceutically relevant, and the authors themselves note the need for isolation of active constituents.

5.6 Anticholinesterase / Neuroprotective Activity

The aqueous extract of U. picta inhibited acetylcholinesterase and butyrylcholinesterase in a dose-dependent manner. Phenols and flavonoids are present in the extract, and the extract scavenged ABTS radical and hydroxyl radical in a dose-dependent manner. This inhibition of cholinesterases together with antioxidant properties has been interpreted as a potential means for treating or managing Alzheimer's disease, though this remains entirely speculative at the current state of research.

Evidence strength: In vitro only. No in vivo animal or human data on neurological outcomes have been published specifically for U. picta in the reviewed literature.

5.7 Antidiabetic Activity

Antidiabetic effects were observed in streptozotocin-induced diabetic Wistar mice, where oral leaf extracts at 150–300 mg/kg for 100 days reduced blood glucose, glycosylated haemoglobin, and lipid profiles while increasing body weight and liver glycogen, indicating hypoglycemic and antihyperlipidemic activity.

Evidence strength: Animal model data only (streptozotocin-induced diabetes). No human glycaemic trials have been reported.

5.8 Cardiovascular / Pulmonary Effects

The extracts and isolated components have shown in vitro and in vivo pharmacological effects including effects on urinary tract diseases, tumors, edema, smoking, and dyspnea. Research by Occhiuto et al. (cited in multiple reviews) investigated the comparative haemodynamic effects of the flavonoid rhoifolin in experimental animal models, as well as comparative effects of rhoifolin on experimental pulmonary hypertension. These studies relate to properties of isolated rhoifolin, not to U. picta preparations tested in humans.

Evidence strength: Animal pharmacology for isolated constituents; no human cardiovascular or pulmonary trials for U. picta extracts or preparations.

5.9 Urinary Tract and Genitourinary Effects

Leaves have traditionally been attributed antiseptic properties and are used in the treatment of wounds, genitourinary infections, and urinary disorders. Powdered leaves have been used ethnomedicinally for gonorrhoea. These applications represent traditional ethnomedicinal use without controlled clinical validation.

5.10 Antiparasitic / Acaricidal Activity

Laboratory evaluation of acaricidal properties of extracts from Uraria picta (Leguminosae) was reported by Igboechi et al. in the Journal of Ethnopharmacology (1989). The whole plant also shows antivenom activity against Echis carinata. These are early preclinical observations.

6. Body Systems and Health Areas of Association

• Musculoskeletal system: Leaf pastes serve as poultices for rheumatism and inflammatory conditions; these uses stem from reputed anti-inflammatory and analgesic effects in folk healing practices across Asia.
• Respiratory system: Traditionally used for respiratory infections, cardiovascular disorders, fever, parasitic worm infestations, and microbial infections as one of the ingredients of Dashmula.
• Hepatic system: Hepatoprotective activity has been reported in recent years.
• Urinary/genitourinary system: Traditional use in urinary tract disorders and genitourinary infections is documented ethnomedicinally.
• Neurological system: Anticholinesterase activity has been reported, alongside antioxidant, antimicrobial, hepatoprotective, anti-inflammatory, and antidiabetic activities.
• Metabolic system: Antidiabetic and antihyperlipidemic effects observed in animal models.
• Immune and anti-infective systems: Antimicrobial effects against both Gram-positive and Gram-negative bacteria and fungi demonstrated in vitro.
• Oncology (exploratory): Potential pharmacological effects including anticancer properties have been reported for crude extracts and independent components, though further investigation is required.

7. Dosage Forms and Dosages Reported in Studies

All dosages listed below are exactly as reported in source publications and refer to experimental models unless otherwise noted.

• Anti-inflammatory (rat model): Methanol extract of roots (UPME) tested at doses of 100, 200, and 400 mg/kg, oral administration, in experimental rat models.
• Anti-inflammatory (rat, comparative): Whole-plant methanolic extract administered orally at dose levels of 200 and 400 mg/kg body weight.
• Anticancer (rodent): MEUP at the higher dose of 400 mg/kg was found more effective in reducing cancer growth.
• Antidiabetic (mouse model): Oral leaf extracts at 150–300 mg/kg for 100 days.
• Traditional decoction (Ayurvedic): Classical texts recommend 3–6 grams of root powder daily in decoction form for internal use.
• Antimicrobial (in vitro MIC): MIC values for isolated isoflavanones were in the range of 12.5–200 µg/ml against bacteria and fungi.

No established standardized clinical dosing exists in regulatory pharmacopoeias (such as the WHO monographs, European Pharmacopoeia, or USP) for Uraria picta as a standalone supplement.

8. Safety Considerations

Toxicological Profile

Despite being traditionally used therapeutically as one of the ingredients of Dashmula, comprehensive studies on the phytochemical composition and safety profile of the plant remain limited. Due to its broad ethnomedicinal uses, the applications of the genus Uraria have been widely studied in laboratory conditions, but systematic research on the toxicity profile of this plant is still deficient and needs revalidation.

The toxicity profile of U. picta extracts indicates general safety at traditional and tested doses, with no mortality observed in mice at acute oral doses up to 10 g/kg body weight over 14 days. Subacute studies in rats at 2000 mg/kg showed no significant adverse effects on haematology or histopathology, though higher doses in some plant extracts may induce mild gastrointestinal upset; LD50 values exceed 2000 mg/kg, supporting a low toxicity profile.

Adulteration Risk

With its growing rarity, the plant is easily substituted by other close relatives, and thus medicines using this plant as an ingredient may get adulterated. This adulteration risk is heightened by the depletion of wild stocks, meaning formulations purporting to contain U. picta may not deliver the authentic ingredient.

Conservation Status and Supply-Side Concerns

U. picta is commercially important and in high demand in India and Western African countries. As a consequence, U. picta has now been classified as a rare, endangered, and threatened (RET) species in India. Harvesting U. picta from the wild is prohibited in Uttarakhand and other parts of India. Depletion from the wild has occurred due to overexploitation by local tribes and pharmaceutical companies, and poor seed viability has added to the problem. These supply constraints have practical implications for the reliability and consistency of products containing U. picta.

Geographic Variability and Quality Consistency

In India, the plant is native to many regions such as parts of Uttarakhand and Madhya Pradesh, but due to vast geographical diversity, the plant can have different toxicity and efficacy. A study confirmed the effect of environmental factors on genetic variations within the same species. This variability means that batch-to-batch consistency of extracts or raw material cannot be assumed without standardization.

Gaps in Clinical Safety Data

Despite the reliance on therapeutic checkpoints underscoring its ethnopharmacological significance, comprehensive studies on the phytochemical composition and safety profile of the plant remain limited. The uses remain uncertain because raw plant parts or crude extracts are being used in all formulations. Extensive investigations are necessary to focus on the identification of these phytochemicals and their safety profiles.

9. Regulatory and Conservation Context

Uraria picta is a key ingredient of more than a hundred Ayurvedic formulations and an important component of many patents in countries like India, China, Japan, and the USA. However, it is not currently listed in any major Western pharmacopoeia (e.g., the European Pharmacopoeia, USP, or British Pharmacopoeia) as a standalone herbal ingredient, and it has not been evaluated in a regulatory monograph by bodies such as the WHO, ESCOP, or the European Medicines Agency (EMA). Searches of patent databases found almost seven applications, highlighting the differences between a large number of published scientific articles and few formal patent applications.

There are still gaps requiring scientific evaluation. In summary, knowledge of U. picta in traditional uses, its origins, chemical components, pharmacological activities, and toxicology has shown that U. picta supports further research into the development of new herbal and health products. Subsequent research ought to concentrate on in-depth, mechanism-based investigations using clinical trials and animal models.

References

• URARIA PICTA (JACQ.): A Review on Ethnomedical Uses, Phytochemistry, and Biological Activities — Asian Journal of Pharmaceutical and Clinical Research (2017)
• Uraria picta: A review on its ethnobotany, bioactive compounds, pharmacology and commercial relevance — South African Journal of Botany / ScienceDirect (2024)
• Uraria picta: A review on its ethnobotany, bioactive compounds, pharmacology and commercial relevance — ResearchGate (2024)
• Benefaction of Medicinal Plant Uraria picta — IntechOpen (2022)
• Anticancer studies on methanolic extract of aerial parts of Uraria picta (Jacq.) DC — Future Journal of Pharmaceutical Sciences / SpringerOpen (2021)
• Isoflavanones from Uraria picta and their antimicrobial activity — Phytochemistry (2007), PubMed PMID: 17540419
• Anti-inflammatory and hepatoprotective activities of the roots of Uraria picta — International Journal of Green Pharmacy (2017)
• Phytochemical screening and elemental analysis in different plant parts of Uraria picta Desv.: A Dashmul species — ResearchGate (2014)
• Uraria picta: A comprehensive review on evidences of utilization and strategies of conservation — ResearchGate (2021)
• Flavone Glycoside Based Validated RP-LC Method for Quality Evaluation of Prishniparni (Uraria picta) — Chromatographia (2009) / ResearchGate
• Phytochemical analysis and toxicity evaluation of Uraria picta (Jacq.) Desv. ex DC. through In Vitro and In Vivo approaches — ScienceDirect (2025)
• A Comprehensive Review of Prishniparni (Uraria picta Desv. Ex DC.) in Brihatrayee and various Nighantus — Journal of Ayurveda and Integrated Medical Sciences (2025)
• Prishnaparni / Uraria picta — Ayurvedic Overview, Benefits, Uses — Planet Ayurveda (2025)
• Isoflavanones from Uraria picta and their antimicrobial activity — ResearchGate / Phytochemistry (2007)
• Uraria picta (Jacq.): A Review on Ethnomedical Uses, Phytochemistry, and Biological Activities — DocsLib